CD8A and neoplasm: This is highlighted in tumor with T-cell-inflamed TME, containing abundant infiltration of CD8+ T cells (67), and thus predicting a better clinical outcome due to priming for the efficacy of immunotherapy (68), unlike the non-T-cell-inflamed TME.